Qingdao Baheal Pharmaceutical Co., Ltd. offers contract manufacturing and CDMO services for oral solid dosage forms to Marketing Authorization Holders (MAHs) with Class B Licenses.

In strict compliance with the Marketing Authorization Holder (MAH) system, we have established a robust quality management system for contract manufacturing. We boast a specialized R&D team capable of China-U.S. dual registration, with multiple products already successfully commercialized in the U.S. market.

The company has robust pharmaceutical R&D capabilities, including osmotic pump technology, delayed-release technology, local action technology, membrane-controlled technology, matrix sustained-release technology, and solubilization technology for poorly soluble drugs. It operates multiple production workshops complying with regulatory requirements of China and the United States, capable of manufacturing tablets (conventional tablets, controlled-release tablets, sustained-release tablets, etc.), capsules, granules, dry suspensions and other dosage forms. At present, multiple CDMO projects have completed product handover and entered commercial production.